Moderna’s Variant COVID-19 Vaccine Starts Clinical Trial


  • The first clinical trial testing a variant-specific COVID-19 shot launched Wednesday.
  • The NIH-sponsored study will test an updated version of Moderna’s coronavirus vaccine. 
  • The shot is designed to fight the B.1.351 strain first identified in South Africa.
  • See more stories on Insider’s business page.

The first clinical trial to test an updated version of a coronavirus vaccine began Wednesday.

US researchers are testing a shot made by Massachusetts biotech Moderna that’s tailored to neutralize a concerning variant of the novel coronavirus. The research is the latest escalation in society’s battle against variants of the virus. Experts worry that specific mutations in the virus’ spike protein, the target of coronavirus vaccine, could partially lower protection from vaccines.

The variant first found in South Africa, called the B.1.351 variant, has been especially concerning. Data from testing in petri-dishes found this version of the virus led to a significant decrease in neutralizing antibodies, the virus-fighting proteins generated by the vaccine. While the leading vaccines are still believed to help protect against this strain, virologists fear the reduced immune response could lead to shorter durability of protection. 

In response, leading vaccine developers have started research on versions of their shots tailored against B.1.351. Moderna has become the first to start human testing of a variant-focused shot, with this study being run by the US National Institutes of Health.

NIH researchers expect to enroll 210 healthy American adults in this study by the end of April in the Atlanta, Cincinnati, Nashville, and Seattle areas. Sixty of those volunteers will be selected from a previous study of Moderna’s original COVID-19 shot.

The study will test a range of dosing options, including different dose strengths and receiving either two or three shots. 

The NIH did not specify when results are expected, and Moderna did not immediately respond to a request for comment on the timeline. Jefferies biotech analyst Michael Yee estimated Tuesday in a note to investors that data for this variant-specific vaccine should be “likely coming in the next few months.”

LoadingSomething is loading.



Source link

Get in Touch

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Man Picks Up And Hurls Away Rabid Bobcat In Wild Viral Footage

A man was seen swiftly picking up and tossing away a bobcat that attacked a woman on their front driveway in a viral video...

Trash Can Relay

Purpose To help improve throwing accuracy and ability to get a ball from outfield to the infield. Set Up Divide players into two teams. Position one team...

After Initial Cancellation, CIF-San Diego Championships Back On

After initially announcing the cancellation of the meet due to ongoing Covid-19 measures, the San Diego Section of the California Interscholastic Federation (CIF)...

Get in Touch

21,805FansLike
2,507FollowersFollow
17,500SubscribersSubscribe

Latest Posts

Man Picks Up And Hurls Away Rabid Bobcat In Wild Viral Footage

A man was seen swiftly picking up and tossing away a bobcat that attacked a woman on their front driveway in a viral video...

Trash Can Relay

Purpose To help improve throwing accuracy and ability to get a ball from outfield to the infield. Set Up Divide players into two teams. Position one team...

After Initial Cancellation, CIF-San Diego Championships Back On

After initially announcing the cancellation of the meet due to ongoing Covid-19 measures, the San Diego Section of the California Interscholastic Federation (CIF)...

Volleyball TV & Streaming Listings

You love volleyball and you know how important our free coverage of our sport is to you. Get one or all of these great...

Ortega Coming Back

Image: Photographer Name: PHOTO BY PEYTON WILLIAMSArticle Summary Title: Ortega Coming BackPath: https://www.uslaxmagazine.com/college/women/jamie-ortega-to-return-to-north-carolina-for-2022-season Source link